Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and car...
Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC...
Ozempic Maker Novo Nordisk Is a Problem as Denmark's Economy Hits a Wall
The economy ministry blamed the slowdown on U.S. tariffs, but faltering demand for Ozempic and Wegovy could be another factor.
Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown
Denmark on Friday slashed its annual growth forecast to 1.4% from 3%. In this article NOVO.B-DK
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Novo Nordisk: The Falling Knife That Keeps Giving
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in...
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
I invest for long-term total return, prioritizing dividend growth and quality companies trading at bargain valuations, especially during industry downturns. Despite current headwinds like tariffs a...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nord...
Why I Tripled My Novo Nordisk Position
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages. Despite lowered 2025 guidance and slower growth, core produ...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadl...
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors...
Why Novo Nordisk Stock Flew Higher on Friday
On Friday, the stock of Novo Nordisk (NVO 4.70%) continued to be affected by results from the lab the previous day. The interesting twist: It wasn't the company conducting the research.
Novo Nordisk: This Won't Last
Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-te...
The rise, fall and rise again of Novo Nordisk shares
CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
Novo Nordisk: Is there life after slow death for slimmed down drug maker?
After a brutal 52% slide this year (not helped by a surprise profit warning last week), Novo Nordisk (NYSE:NVO) is struggling to regain its footing. Wednesday's second-quarter results confirmed the...
Novo Norisk: The struggle is real and getting harder by the day
After last week's profit warning and leadership shake-up, Novo Nordisk's latest earnings update offered little new, though the company's growing struggle against rivals such as Eli Lilly and cheape...
Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.
Related Companies